KBR 7785

Drug Profile

KBR 7785

Latest Information Update: 26 Mar 2008

Price : $50

At a glance

  • Originator Nippon Organon
  • Class Antihyperglycaemics; Antirheumatics; Hydroxamic acids; Small molecules
  • Mechanism of Action Matrix metalloproteinase 1 inhibitors; Matrix metalloproteinase 3 inhibitors; Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer; Graft-versus-host disease; Type 2 diabetes mellitus

Most Recent Events

  • 19 May 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Japan (Parenteral)
  • 12 Mar 2002 A study has been added to the Diabetes pharmacodynamics section
  • 01 Jun 2000 An animal study has been added to the pharmacodynamics section of transplant rejection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top